



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0


F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

BR351a : Poorly differentiated breast cancer tissue array, including TNM, clinical stage and pathology grade, 35 cases/35 cores, replacing BR351

Microarray Panel	Breast invasive carcinoma of no special type tissue microarray, containing 35 cases of Low differentiated invasive carcinoma , single core per case		
Cores	35		
Cases	35		
Row number	5		
Column number	7		
Core Diameter (mm)	2		
Thickness (µm)	5		
Tissue Array Type	FFPE		
Species	Human		
Applications	54		
Notes	1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours. In the following specsheet, "*" means invalid core; "-" means no applicable or negative in IHC markers.		

	1	2	3	4	5	6	7
A	Bre	Bre	Bre	Bre	Bre	Bre	Bre
B	Bre	Bre	Bre	Bre	Bre	Bre	Bre
C	Bre	Bre	Bre	Bre	Bre	Bre	Bre
D	Bre	Bre	Bre	Bre	Bre	Bre	Bre
E	Bre	Bre	Bre	Bre	Bre	Bre	Adn

Legend:Bre - Breast

● - Malignant tumor, ● - Malignant tumor (stage IIA), ● - Malignant tumor (stage IIB), ● - Malignant tumor (stage IIIA), ● - Malignant tumor (stage IIIB), ● - Malignant tumor (stage IV)

, tissue IDs are available in exported Excel files.

Pos.	No.	Age	Sex	Organ/Anatomic Site	Pathology diagnosis	TNM	Grade	Stage	Type	Image
A1	1	37	F	Breast	invasive carcinoma of no special type	T4N2M0	2--3	IIIB	malignant	
A2	2	43	F	Breast	invasive carcinoma of no special type	T2N0M0	2--3	IIA	malignant	
A3	3	49	F	Breast	invasive carcinoma of no special type	T2N0M0	3	IIA	malignant	
A4	4	54	F	Breast	invasive carcinoma of no special type	T2N0M0	2--3	IIA	malignant	
A5	5	58	F	Breast	invasive carcinoma of no special type	T2N0M0	2--3	IIA	malignant	
A6	6	44	F	Breast	invasive carcinoma of no special type	T2N0M0	3	IIA	malignant	
A7	7	70	F	Breast	invasive carcinoma of no special type	T2N0M0	3	IIA	malignant	
B1	8	29	F	Breast	invasive carcinoma of no special type	T2N0M0	3	IIA	malignant	
B2	9	48	F	Breast	invasive carcinoma of no special type	T2N0M0	3	IIA	malignant	
B3	10	59	F	Breast	invasive carcinoma of no special type	T4N0M0	3	IIIB	malignant	
B4	11	70	F	Breast	invasive carcinoma of no special type	T4N2M1	3	IV	malignant	
B5	12	68	F	Breast	invasive carcinoma of no special type	T2N2M0	3	IIIA	malignant	
B6	13	48	F	Breast	invasive carcinoma of no special type	T2N0M0	3	IIA	malignant	
B7	14	67	F	Breast	invasive carcinoma of no special type	T2N0M0	3	IIA	malignant	
C1	15	43	F	Breast	invasive carcinoma of no special type	T2N0M0	3	IIA	malignant	
C2	16	23	F	Breast	invasive carcinoma of no special type	T2N0M0	3	IIA	malignant	
C3	17	68	F	Breast	invasive carcinoma of no special type	T2N0M0	3	IIA	malignant	
C4	18	63	F	Breast	invasive carcinoma of no special type	T2N0M0	3	IIA	malignant	
C5	19	48	F	Breast	invasive carcinoma of no special type	T3N0M0	3	IIB	malignant	
C6	20	49	F	Breast	invasive carcinoma of no special type	T3N1M0	3	IIIA	malignant	
C7	21	52	F	Breast	invasive carcinoma of no special type	T2N0M0	3	IIA	malignant	
D1	22	52	F	Breast	invasive carcinoma of no special type	T3N0M0	3	IIB	malignant	
D2	23	47	F	Breast	invasive carcinoma of no special type	T2N0M0	3	IIA	malignant	
D3	24	60	F	Breast	invasive carcinoma of no special type	T2N0M0	3	IIA	malignant	
D4	25	81	F	Breast	invasive carcinoma of no special type(ductal tissue)	T3N0M0	-	IIB	malignant	
D5	26	64	F	Breast	invasive carcinoma of no special type	T4N0M0	3	IIIB	malignant	
D6	27	65	F	Breast	invasive carcinoma of no special type	T2N1M0	3	IIB	malignant	

D7	28	80	F	Breast	invasive carcinoma of no special type	T3N0M0	3	IIB	malignant	
E1	29	57	F	Breast	invasive carcinoma of no special type	T3N0M0	3	IIB	malignant	
E2	30	51	F	Breast	invasive carcinoma of no special type	T2N0M0	3	IIA	malignant	
E3	31	68	F	Breast	invasive carcinoma of no special type	T4bN0M0	3	IIIB	malignant	
E4	32	41	F	Breast	invasive carcinoma of no special type	T2N0M0	3	IIA	malignant	
E5	33	42	F	Breast	invasive carcinoma of no special type	T2N2M0	3	IIIA	malignant	
E6	34	48	F	Breast	invasive carcinoma of no special type	T4N1M0	3	IIIB	malignant	
E7	35	69	F	Breast	invasive carcinoma of no special type	T4aN1M0	3	IIIB	malignant	
-	0	42	M	Adrenal gland	Pheochromocytoma (tissue marker)		-		Malignant	

AMSBIO | www.amsbio.com | info@amsbio.com

AMSBIO LLC
USA & Canada 
1035 Cambridge Street,
Cambridge, MA 02141
T: +1 (617) 945-5033 or
T: +1 (800) 987-0985
F: +1 (617) 945-8218

AMSBIO Europe BV
EU 
Berenkoog 41,
1822 BH Alkmaar,
Netherlands
T: +31 (0) 72 8080244
F: +31 (0) 72 8080142

AMS Biotechnology (Europe) Ltd
UK & Rest of the World 
184 Park Drive, Milton Park
Abingdon OX14 4SE
T: +44 (0) 1235 828 200
F: +44 (0) 1235 820 482

AMS Biotechnology (Europe) Ltd
Switzerland 
Via Lisano 3,
(CP.683)
CH-6900 Massagno
T: +41 (0) 91 604 55 22
F: +41 (0) 91 605 17 85

AMSBIO Europe BV
Deutschland 
T: +49 (0) 69 779099
F: +49 (0) 69 13376880